Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Increased transvascular retention of atherogenic lipoproteins in type 2 diabetes relates to their enhanced proteoglycan binding
Pär Björklund, Jennifer Härdfeldt, Lauri Äikäs, Sara Straniero, Minna Holopainen, Katariina Öörni, Mats Rudling, Bo Angelin
Pär Björklund, Jennifer Härdfeldt, Lauri Äikäs, Sara Straniero, Minna Holopainen, Katariina Öörni, Mats Rudling, Bo Angelin
View: Text | PDF
Research Article Clinical Research Metabolism Vascular biology

Increased transvascular retention of atherogenic lipoproteins in type 2 diabetes relates to their enhanced proteoglycan binding

  • Text
  • PDF
Abstract

Subendothelial retention of cholesterol-rich apolipoprotein-B–containing lipoproteins drives atherosclerotic arterial disease. In peripheral interstitial fluid from patients with type 2 diabetes (T2D), levels of such particles have been shown to be paradoxically reduced relative to those in serum, presumably reflecting their increased retention within the arterial wall. To identify possible mechanisms involved in lipoprotein retention in T2D, we obtained serum and skin blister fluid from such patients and matched controls, together with skin biopsies in a subset of individuals. In T2D, smaller LDL and VLDL remnant particles were more prominent in serum but not in interstitial fluid, reflecting their enhanced vascular entrapment. The interstitial-fluid-to-serum ratio of apolipoprotein-B was 58% lower in T2D than in controls (0.14 versus 0.33), concomitant with increased susceptibility for LDL binding to proteoglycans. The most marked differences were seen in patients with clinically evident cardiovascular disease. The degree of transvascular retention was positively related to the propensity of isolated serum LDL to bind aortic proteoglycans, both in T2D and in controls. Skin unesterified cholesterol levels were higher in patients with T2D relative to healthy controls. With aging, both proteoglycan binding and apparent vascular retention of LDL increased in controls but not in T2D, indicating that these mechanisms may also be relevant for atherogenesis in nondiabetic individuals.

Authors

Pär Björklund, Jennifer Härdfeldt, Lauri Äikäs, Sara Straniero, Minna Holopainen, Katariina Öörni, Mats Rudling, Bo Angelin

×

Figure 5

Serum LDL aggregation susceptibility and LDL modifications.

Options: View larger image (or click on image) Download as PowerPoint
Serum LDL aggregation susceptibility and LDL modifications.
(A) Serum LD...
(A) Serum LDL aggregation susceptibility. LDL aggregation curves: aggregate size (nm) versus time (min) after induction of aggregation with human recombinant sphingomyelinase. Inflection point (EC50) of the aggregation curves: the faster the particles aggregate, the shorter the time required to reach the inflection point. Aggregate sizes at 2 h calculated from aggregation curves. EC50 of aggregation curves stratified for MACE. (B) Serum LDL modifications. %Glycated serum LDL adjusted for LDL cholesterol, serum OX-LDL adjusted for serum LDL cholesterol, %Glycated LDL cholesterol stratified for MACE, and serum OX-LDL adjusted for LDL cholesterol stratified for MACE. Data are from 74 patients with T2D and 74 controls and presented as mean ± SD (LDL aggregation curves), median (violin plot), or median, upper and lower quartiles, and range (box-and-whisker plots). Controls versus T2D, Student’s t test or Mann-Whitney U test. C, C+MACE, T2D-MACE, T2D+MACE, 1-way ANOVA with Benjamini and Hochberg FDR correction. ***P < 0.001 versus controls; ##P < 0.01 versus –MACE. MACE, major cardiovascular event; OX-LDL, oxidized LDL.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts